Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

By sjmartinez • March 3, 2023

Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-4342. doi: 10.1002/cam4.5308. Epub 2022 Dec 4. PMID: 36464853; PMCID: PMC9972135.

Tags: dose intensity, Endocrinology, Harbor UCLA, HRQoL, kinase inhibitor, lenvatinib, Quality of Life, radioiodine-refractory differentiated thyroid cancer

Menopausal Transition and Thyroid Function Trajectories: A Large-Scale Longitudinal Study of Healthy Women

Hayashi S, Fukui S, Leung AM, Noto H, Inoue K. Menopausal Transition and Thyroid Function Trajectories: A Large-Scale Longitudinal Study of Healthy Women. J Clin[...]

E. Dale Abel, MD, PhD Awarded Jamaica’s Order of Distinction, Commander Class

The UCLA Department of Medicine is proud to announce that E. Dale Abel, MD, PhD, chair and executive medical director of the Department of Medicine[...]

Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer

Baclig NV, Chengappa M, Soliman AJ, Jacob S, LeVee A, Fisch S, Face C, Chaudhry S, Idossa D, Poonacha T, Huppert L, Quintal L, Melisko[...]